Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426339 | 0.91 | MAP1LC3B (0.53) | MAPTGAAMAP1LC3BALPLTDP1 | |
| SCHEMBL10672428 | 0.89 | MAPT (0.77) | MAPTGAAMAP1LC3BTDP1TP53 | |
| SCHEMBL12676598 | 0.81 | MAPT (0.47) | MAPTGAAMAP1LC3BTDP1L3MBTL1 | |
| SCHEMBL717834 | 0.79 | ESR2 (0.50) | MAPTGAAMAP1LC3BALPLTDP1 | |
| SCHEMBL1779753 | 0.78 | MAPT (0.63) | MAPTGAAMAP1LC3BTDP1L3MBTL1 | |
| SCHEMBL7688021 | 0.78 | MAPT (0.63) | MAPTGAAMAP1LC3BTDP1TP53 | |
| SCHEMBL11821558 | 0.78 | MAPT (0.63) | MAPTGAAMAP1LC3BTDP1TP53 | |
| SCHEMBL14941706 | 0.78 | MAPT (0.63) | MAPTGAATDP1TP53RECQL | |
| SCHEMBL1176883 | 0.78 | MAPT (0.63) | MAPTGAAMAP1LC3BTDP1TP53 | |
| SCHEMBL5329450 | 0.78 | MAPT (0.57) | MAPTGAATDP1TP53RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123127-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | EVERON BIOSCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2017189553-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | EVERON BIOSCIENCES, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-8883935-B2 | High refractive index composition | BATTELLE MEMORIAL INSTITUTE (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883935-B2 | High refractive index composition | BATTELLE MEMORIAL INSTITUTE (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883935-B2 | High refractive index composition | BATTELLE MEMORIAL INSTITUTE (US) | 2014-11-11 | — | — | US | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2563826-A2 | HIGH REFRACTIVE INDEX COMPOSITION | Battelle Memorial Institute (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130046054-A1 | HIGH REFRACTIVE INDEX COMPOSITION | BATTELLE MEMORIAL INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130046054-A1 | HIGH REFRACTIVE INDEX COMPOSITION | BATTELLE MEMORIAL INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130046054-A1 | HIGH REFRACTIVE INDEX COMPOSITION | BATTELLE MEMORIAL INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-7189851-B2 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-1229019-A1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLIC ENAMINONE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-08-07 | — | — | EP | disclosed |
| US-6350749-B1 | SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-26 | — | — | US | disclosed |
| EP-1057812-A1 | AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-3947449-A | Tetrahydroacridones having chemotherapeutic action and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | CALCRL, CALCR, CALCB | MAPT 3734/4885GAA 3218/4885MAP1LC3B 4104/4885 |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | MAPT 4656/4885GAA 3421/4885MAP1LC3B 4624/4885 |
| US-20200123127-A1 | REMOVAL OF SENESCENCE-ASSOCIATED MACROPHAGES | CD68, CD47, ARG1 | MAPT 3397/4885GAA 964/4885MAP1LC3B 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.